CareDx Inc (NASDAQ:CDNA) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 15, 2016
Having a price of $4.43, CareDx Inc (NASDAQ:CDNA) traded 3.84% lower on the day. With the last stock price down 9.77% from the two hundred day average, compared to the S&P 500 which has fallen -0.01% over the same period. CareDx Inc has been tracking to a 50-day average of $4.70 and two hundred day moving average of $4.72. Volume of trade was was up over the average, with 27,293 shares of CDNA changing hands over the typical 18,739 shares.
Zacks Investment Research has upgraded CareDx Inc(NASDAQ:CDNA) to Hold in a statement released 9/15/2016.
CareDx Inc has a one-year low of $3.70 and a 52 week high of $7.19 . CDNA’s total market value is presently $0.0.
About CareDx Inc (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, and which provides complementary information to help personalize long-term care of heart transplant recipients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.